18As antibiotic-resistant bacterial pathogens become an ever-increasing concern, antimicrobial peptides (AMPs) have 19 grown increasingly attractive as alternatives. Potentially, plants could be used as cost-effective AMP bioreactors; 20 however, reported heterologous AMP expression is much lower in plants compared to E. coli expression systems 21 and often results in plant cytotoxicity, even for AMPs fused to carrier proteins. We wondered if there were a 22 physical factor that made heterologous AMPs difficult to express in plants. Using a meta-analysis of protein 23 databases, we determined that native plant AMPs were significantly less cationic than AMPs native to other taxa.
24To apply this finding to plant expression, we tested the transient expression of 10 different heterologous AMPs, 25 ranging in charge from +7 to -5, in the the tobacco, Nicotiana benthamiana. We first tested several carrier proteins 26 and were able to express AMPs only with elastin-like polypeptide (ELP). Conveniently, ELP fusion allows for a 27 simple, cost-effective temperature shift purification. Using the ELP system, all five anionic AMPs expressed well,
28with two at unusually high levels (375 and 563 µg/gfw). Furthermore, antimicrobial activity against Staphylococcus 29 epidermidis was an order of magnitude stronger (average MIC = 0.26 µM) than that typically seen for AMPs 30 expressed in E. coli expression systems. Unexpectedly, this high level of antimicrobial activity was associated with 31 the uncleaved fusion peptide. In contrast, all previous reports of AMPs expressed in both plant and E. coli 32 expression systems show cleavage from the fusion partner to be required before activity is seen. In summary, we 33 describe a means of expressing AMP fusions in plants in high yield, purified with a simple temperature-shift 34 protocol, resulting in a fusion peptide with high antimicrobial activity, without the need for a peptide cleavage step. 35 36 37 42 antibiotics has led to pathogenic and commensal bacteria incorporating and retaining genes for detoxification or 43 export of antibiotics, inevitably resulting in resistance to all new antibiotics introduced (Aminov et al. 2010; Thung 44 et al., 2015; Enright et al. 2002; Nathan and Cars, 2014).45 Both of these undermining factors are addressed by antimicrobial peptides (AMPs). First, the resources 46 available to develop new AMP drugs is vast and recombinant peptide variants can be quickly generated, unlike the 47 slow discovery and development cycle for antibiotics. AMPs are abundant across the taxa, being found in 48 vertebrates, insects, fungi and plants. Thousands of AMPs have been isolated and tested experimentally (Wang et 49 al., 2015) and many more can be discovered using algorithms to scan genome data bases (Islam et al., 2018b).50 Second, though resistance to AMPs has been shown to develop in bacteria (Kubicek-Sutherland et al., 2017), the 51 multiple antimicrobial activities and low affinity targets typical of AMPs have been thought to make them more 52 difficult targ...